Literature DB >> 4421998

Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.

R R Almon, C G Andrew, S H Appel.   

Abstract

Serum factors that inhibit the binding of (125)I-labeled alpha-bungarotoxin to the acetylcholine receptor extracted in detergent from denervated rat muscle were detected by a sensitive assay. The serum of at least 5 and possibly 11 out of 15 patients with myasthenia gravis showed inhibitory activity that was localized to the globulin fraction. No controls showed inhibitory activity. The demonstration of inhibitory globulins may help explain the involvement of the immune system in the pathophysiology of the neuromuscular junction in patients with myasthenia gravis.

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4421998     DOI： 10.1126/science.186.4158.55

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  76 in total

1.  Myasthenia gravis and the thymus gland.

Authors: 
Journal:  West J Med       Date:  1975-08

2.  Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis.

Authors:  I Kaplan; B T Blakely; G K Pavlath; M Travis; H M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 3.  Intrathymic expression of neuromuscular acetylcholine receptors and the immunpathogenesis of myasthenia gravis.

Authors:  Arnold I Levinson; Yi Zheng; Glen Gaulton; Decheng Song; Jonni Moore; C Hank Pletcher
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Immunoglobulin heavy chain gene associations in myasthenia gravis: new evidence for disease heterogeneity.

Authors:  A Demaine; N Willcox; M Janer; K Welsh; J Newsom-Davis
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

Review 5.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

6.  A cholinoceptor antiserum: its pharmacological properties.

Authors:  F Berti; F Clementi; B Conti-Tronconi; G C Folco
Journal:  Br J Pharmacol       Date:  1976-05       Impact factor: 8.739

7.  A radioimmunoassay for the quantitative evaluation of anti-human acetylcholine receptor antibodies in myasthenia gravis.

Authors:  V M Monnier; B W Fulpius
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

Review 8.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

9.  Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia.

Authors:  A Corsini; P Roma; D Sommariva; R Fumagalli; A L Catapano
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

10.  Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus.

Authors:  J G Wilson; R M Jack; W W Wong; P H Schur; D T Fearon
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.